Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1235 in relapsed/refractory AML
NCT02864290Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Nov 2016
- Primary completion
- Sep 2020
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 1, open-label trial of ASP1235 in acute myeloid leukemia (AML) (6 arms), sponsored by Astellas Pharma. Primary endpoint: Incidence and nature of adverse events up to 30 months. Started Nov 2016; status: terminated.
02
Drugs
ASP1235
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02864290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864290.